Biogen Idec introduced that in fact detailed constructive data from CONFIRM, the 2nd Phase 3 tests of oral BG-12 in individuals with relapsing-remitting multiple sclerosis (RRMS), will be introduced in three platform shows along at the 64th Annual Meeting of a typical American Academy of Neurology (AAN) in New Orleans. In CONFIRM, BG-12 proved performance across a number of medical and radiological end result actions, in addition to favorable security and tolerability personal profiles.
"Outcome from CONFIRM partner the professional-profile we have now seen for BG-12 through its clinical progress program, which generally now includes tough facts sets from two global, placebo-controlled Phase 3 crucial research with greater than 2,600 multiple sclerosis (MS) affected individuals," said, Douglas E. Williams, Ph.D., Biogen Idec's executive vice chairman of Research and Development.
No comments:
Post a Comment